Vetnosis publishes Prospects for Pet Ectoparasiticides

Edinburgh, UK - 31^st July 2008 - Vetnosis publishes Prospects for Pet Ectoparasiticides

Vetnosis has published Prospects for Pet Ectoparasiticides, a global study of the future for the pet ectoparasiticides category and its key players.

The pet ectoparasiticides category is the largest category in companion animal medicine today and has been the primary growth driver within the companion animal sector.  In real terms, this category has grown more than four times faster than the animal health market in the past decade. This extraordinary growth has been driven by product innovations that met the veterinary profession's significant unmet medical and commercial needs, and the exceptional investment by the industry in creating strong consumer brands and successful commercial strategies.

In Prospects for Pet Ectoparasiticides we present our independent and objective research-driven analysis of the risks and opportunities relating to in-line branded products, branded generics, private label generics, distribution channel changes and product innovation to 2017.  The reports presents our baseline outlook and forecast for the category together with an impact assessment for seven other commercial scenarios that could materialise during the outlook period.

Prospects for Pet Ectoparasiticides offers a fascinating and timely, independent analysis of the largest companion animal category; where this market is heading and who is set to win or lose within our baseline outlook and other commercial scenarios.

For further information on Prospects for Pet Ectoparasiticides please contact Tim Evans.
 
Tim Evans
Managing Director
T: +44 (0)131 718 0772
Email: tim.evans@vetnosis.com